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Summary
Objective: To evaluate the effects of avocado soybean unsaponiﬁables (ASU) on proinﬂammatory mediators in chondrocytes and monocyte/
macrophage-like cells.
Design: To determine the dose response of ASU, chondrocytes (5  105 cells/well) were incubated at 5% CO2, 37C for 72 h with (1) control
media alone or (2) ASU at concentrations of 0.3, 0.9, 2.7, 8.3, and 25 mg/ml. Cells were activated with 20 ng/ml lipopolysaccharide (LPS) for
24 h and cell supernatants were analyzed for prostaglandin E2 (PGE2) and nitrite content. Chondrocytes and THP-1 monocyte/macrophages
(5  105 cells/well) were incubated at 5% CO2, 37C for 72 h with (1) control media alone or (2) ASU (25 mg/ml). One set of cells was ac-
tivated for 1 h with LPS (20 ng/ml) for both reverse-transcriptase PCR and real-time PCR analysis of tumor necrosis factor-alpha (TNF-a),
interleukin-1-beta (IL-1b), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) expression. One set of cells was activated
for 24 h to analyze secreted PGE2 and nitrite levels in the cellular supernatant.
Results: ASU reduced TNF-a, IL-1b, COX-2, and iNOS expression in LPS-activated chondrocytes to levels similar to nonactivated control
levels. The suppression of COX-2 and iNOS expression was paralleled by a signiﬁcant reduction in PGE2 and nitrite, respectively, in the
cellular supernatant. ASU also reduced TNF-a and IL-1b expression in LPS-activated monocyte/macrophage-like cells.
Conclusion: The present study demonstrates that the anti-inﬂammatory activity of ASU is not restricted to chondrocytes, but also affects
monocyte/macrophage-like cells that serve as a prototype for macrophages in the synovial membrane. These observations provide a scientiﬁc
rationale for the pain-reducing and anti-inﬂammatory effects of ASU observed in osteoarthritis patients.
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SocietyIntroduction
Osteoarthritis (OA) is a degenerative joint disease character-
ized by inﬂammation of the synovial membrane, erosion of
articular cartilage, and resorption of subchondral bone1e3.
The degenerative changes in osteoarthritic joints are trig-
gered by a series of biochemical events including excess
production of the proinﬂammatory cytokines interleukin-1-
beta (IL-1b) and tumor necrosis factor-alpha (TNF-a). Over-
production of these cytokines stimulates cartilage matrix
degradation by inhibiting the production of proteoglycans
and type II collagen while upregulating the production of
matrix-degrading enzymes such asmatrixmetalloproteinases
(MMPs)4. These cytokines also upregulate the expression
of cyclooxygenase-2 (COX-2) and inducible nitric oxide syn-
thase (iNOS), two potent proinﬂammatory enzymes that lead
to increased synthesis of prostaglandin E2 (PGE2) and nitric
oxide (NO)5,6. Because cartilage degeneration is directly
linked to elevated levels of IL-1b, TNF-a, COX-2, and iNOS
expression, the use of compounds that inhibit the expression
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Received 12 October 2006; revision accepted 16 July 2007.12of these proinﬂammatory mediators is a promising treatment
strategy for managing the catabolic symptoms of OA.
Current treatment options used to manage OA are not
curative and fail to reverse the degenerative process of OA.
Among the commonly used pharmacologic agents are non-
steroidal anti-inﬂammatory drugs (NSAIDs), corticosteroids,
and hyaluronan preparations7e9. NSAIDs, in particular, are
widely used but their prolonged consumption is associated
with serious adverse side effects such as gastrointestinal ul-
cerations8. The need for effective treatment modalities with
fewer side effects has prompted OA patients to consider
complementary approaches to control pain as well as to im-
prove function and quality of life.
One such alternative approach involves the use of avo-
cado soybean unsaponiﬁables (ASU) as a treatment option.
ASU has been used extensively in Europe for the treatment
of connective tissue diseases. A number of clinical studies
have documented the beneﬁcial effect of ASU in the treat-
ment of OA10. Previous prospective, randomized, double-
blind, placebo-controlled parallel-group studies showed
that ASU signiﬁcantly reduced supplemental NSAID use in
patients suffering from OA in the knees and hip11,12. In addi-
tion, ASU signiﬁcantly reduced pain and functional impair-
ment as assessed by the visual analog scale (VAS) and
the algofunctional index11. In another prospective, random-
ized, double-blind, placebo-controlled, clinical trial, ASU49
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ing pain and functional disability as assessed by theVASand
Lequesne’s Functional Index score. In addition, researchers
observed the residual effect of ASU 8months after the end of
treatment, demonstrating the utility of ASU as a possible
symptomatic slow-acting drug for the treatment of OA13. An-
other randomized, double-blind, placebo-controlled study
found that ASU signiﬁcantly reduced the development of joint
space narrowing, suggesting a possible structure-modifying
effect of ASU14. In all studies, adverse side effects associ-
ated with ASU were mild and infrequent. The encouraging
observations demonstrated by these clinical studies suggest
the utility of ASU as an effective OA treatment to ameliorate
pain and joint dysfunction in patients.
Beneﬁcial effects of ASU have also been documented in
animal studies and in cell culture models. In an ovine model
of OA, ASU-treated animals showed a signiﬁcant reduction
in subchondral bone sclerosis, as well as increased proteo-
glycan content and thickness in the articular knee joint15.
In an equine OA model, total gross examination of articular
cartilage erosion and synovial membrane hemorrhage
showed signiﬁcant improvement in horses treated with
ASU compared to placebo treatment16. ASU also increased
the production of transforming growth factor-b (TGF-b) in the
knee joint ﬂuid of a canine model, thereby increasing the
synthesis of matrix components in the joint17. In a study uti-
lizing an in vivo model of cartilage destruction, ASU pre-
served the glycosaminoglycan and hydroxyproline content
in the cartilage tissue, demonstrating a possible chondropro-
tective effect on articular cartilage18. In human articular
chondrocytes stimulated in cultures with IL-1b, ASU sup-
pressed IL-6, IL-8, MIP-1b, PGE2, and NO production
19,20.
Similarly, ASU reversed the catabolic effect of IL-1b in
human ﬁbroblasts by inducing a signiﬁcant decrease in
MMP-2, MMP-3, and tissue inhibitors of matrix metalloprotei-
nase-1 in the presence of IL-1b21. Furthermore, studies
suggest that ASU may have anabolic effects on cartilage
metabolism. ASU restored aggrecan synthesis in IL-
1b-stimulated chondrocytes and enhanced TGF-b1 and
plasminogen activator inhibitor-1 expression in normal chon-
drocytes20,22. Additionally, ASU fully maintained aggrecan
production and type II collagen expression in chondrocytes
cocultured with osteoarthritic subchondral osteoblasts23.
These ﬁndings collectively suggest that the mechanism of
action for ASU involves multiple cell types involved in joint
inﬂammation.
The purpose of this study was to determine whether
ASU acts upon multiple cell types involved in joint inﬂam-
mation, other than the cell types previously studied. In
particular, we investigated whether the mode of action
of ASU involves monocyte/macrophages, in addition to
chondrocytes and ﬁbroblasts found in the joint. Macro-
phages are bone marrow-derived cells of the monocyte
system found in abundance in the synovial lining during
inﬂammation24. Previous studies have reported that syno-
vial membrane cells, such as macrophages, are important
regulators of cytokine synthesis, inﬂammation, and carti-
lage degradation in osteoarthritic joints25,26. In the present
study, we used a monocyte/macrophage-like cell model to
evaluate the effects of ASU on biomarkers that are impor-
tant in the inﬂammatory process. We evaluated the effect
of ASU on IL-1b, TNF-a, COX-2, and iNOS gene expres-
sion as well as PGE2 and NO production in cultured
chondrocytes and monocytes. By elucidating the cellular
targets of ASU, we can further clarify how this extract
provides symptomatic relief in patients suffering from in-
ﬂammatory disorders such as OA.Materials and methods
CELL CULTURE
Articular chondrocytes were isolated from the radiocarpal
joints of mature Holsteins by digestion of the tissue with
type II collagenase (220 U/ml, GIBCO, Invitrogen Corpora-
tion, Carlsbad, CA, USA) for 12e18 h at 37C. The isolated
cells were ﬁltered through a wire mesh screen to remove
debris, and rinsed four times with Hank’s Balanced Salt So-
lution (GIBCO, Grand Island, NY, USA). Cells were pel-
leted by centrifugation and resuspended in control media
containing: Dulbecco’s Modiﬁed Eagle Medium: Nutrient
Mix F-12 (Invitrogen) supplemented with 10% fetal bovine
serum (FBS, Invitrogen), 50 mg/ml ascorbic acid (Sigma-Al-
drich, St. Louis, MO, USA), and 50 mg/ml gentamycin (Invi-
trogen). Chondrocytes were counted and assessed for
viability using a hemacytometer and the Trypan-blue exclu-
sion method. Articular chondrocytes were plated in six-well
plates (Costar; Cambridge, MA, USA) at a density of 5 
105 cells/well and maintained at 37C, 5% CO2 for 5 days
prior to use.
Human THP-1 monocyte/macrophage-like cells (Ameri-
can Type Culture Collection, ATCC, Manassas, VA, USA)
were propagated in control media containing: RPMI-1640
medium (Invitrogen) supplemented with 2 mM L-glutamine
(Sigma-Aldrich), 10% FBS (Invitrogen), 1.5 g/l sodium bicar-
bonate (Sigma-Aldrich), 4.5 g/l glucose (Fisher Scientiﬁc,
Pittsburgh, PA, USA), 10 mM 4-(2-hydroxyethyl)pipera-
zine-1-ethanesulfonic acid (HEPES, Sigma-Aldrich), 1.0
mM sodium pyruvate (Sigma-Aldrich) and 0.05 mM b-mer-
captoethanol (Sigma-Aldrich). Cells were pelleted via centri-
fugation and assessed for viability using the Trypan-blue
exclusion method. Viable cells were plated in six-well plates
at a density of 5  105 cells/well and treated the same day.
TREATMENT PROCEDURE
ASU (ASU-NMX 1000, Nutramax Laboratories Inc.,
Edgewood, MD, USA) was dissolved in 100% ethanol
(Sigma-Aldrich) and diluted with cell media to achieve the
required ﬁnal concentrations. The concentration used in
this study was based on the sterol content of the ASU prep-
aration determined previously with gas chromatography
and mass spectrometry and high-performance liquid chro-
matography27. The optimal experimental concentration of
ASU was ﬁrst determined by incubating bovine chondro-
cytes (5  105 cells/well) for 72 h with (1) control media sup-
plemented with 10% FBS or (2) ASU at concentrations of
25, 8.3, 2.7, 0.9, and 0.3 mg/ml. Cells were activated with li-
popolysaccharide (LPS, 20 ng/ml; Sigma-Aldrich) for 24 h
and cellular supernatants were analyzed for secreted
PGE2 and nitrite concentrations. There was no signiﬁcant
effect on PGE2 and nitrite levels at 0.3 or 0.9 mg/ml. At
2.7 mg/ml, there was a slight suppression of PGE2 and ni-
trite levels. The optimal level of suppression was found to
be between 8.3 and 25 mg/ml, and the upper limit of ASU
concentration was selected for the experiment based on
the reported clinical dosage and previous published in vitro
data.
Chondrocytes and monocytes were incubated for 72 h
with (1) control media supplemented with 10% FBS or (2)
ASU-NMX 1000 (25 mg/ml). Following pretreatment, cells
were activated with LPS (20 ng/ml) for (1) 1 h for gene ex-
pression analysis using reverse-transcriptase PCR (RT-
PCR) and (2) 24 h to measure secreted PGE2 and nitrite
levels using immunoassay.
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Total cellular RNA was isolated by lysing the cells with
TRIzol reagent (Invitrogen) and extracted with chloroform
(Sigma-Aldrich). Following vigorous agitation and a 3-min in-
cubation at room temperature, the samples were centrifuged
and the aqueous phase containing RNA was collected. The
RNA was precipitated with isopropyl alcohol (Sigma-Aldrich)
and resuspended in RNase-free water (Fisher Scientiﬁc).
Total RNAwas quantiﬁed with UV spectrophotometry (Spec-
traMax 384, Molecular Devices, Sunnyvale, CA, USA) and
evaluated for RNA concentration and integrity.
COMPLEMENTARY DNA SYNTHESIS
For each sample, 1 mg of total RNA was converted to
complementary DNA (cDNA) using Moloney-Murine Leuke-
mia Virus reverse transcriptase from the Advantage RT-for-
PCR kit (BD Biosciences Clontech, Mountain View, CA,
USA). RT was carried out at 42C for 60 min followed by
heating at 94C for 5 min to stop the cDNA synthesis reac-
tion and to destroy any DNase activity.
SEMIQUANTITATIVE PCR
Semiquantitative RT-PCR was performed using primers
speciﬁc to bovine COX-2 (forward, CTC TTC CTC CTG
TGC CTG AT; reverse, CTG AGT ATC TTT GAC TGT
GGG AG), bovine TNF-a (forward, TAA CAA GCC GGT
AGC CCA CG; reverse GCA AGG GCT CTT GAT GGC
AGA), bovine IL-1b (forward, TTC TCT CCA GCC AAC
CTT CAT T; reverse, ATC TGC AGC TGG ATG TTT
CCA T), bovine iNOS (forward, CGG TGC TGT ATT TCC
TTA CGA GGC GAA GAA GG; reverse, GGT GCT GCT
TGT TAG CAG GTC AAG TAA AGG GC), and bovine glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) (for-
ward, ATT CCA CCC ACG GCA AGT T; reverse CGC
TCC TGG AAG ATG GTG AT) as the housekeeping
gene. Primers speciﬁc for human TNF-a (forward, GAG
TGA CAA GCC TGT AGC CCA TGT TGT AGC; reverse,
GCA ATG ATC CCA AAG TAG ACC TGC CCA GAC T),
human IL-1b (forward, GAA GTA CCT GAG CTC GCC
ATG GAA; reverse, CGT GCA GTT CAG TGA TCG TAC
AGG), and human GAPDH (forward, TGA AGG TCG
GAG TCA ACG GAT TTG GT; reverse, CAT GTG GGC
CAT GAG GTC CAC CAC) as the housekeeping gene
were also used. Thermal cycling was performed on the
MJ Research Tetrad Thermal Cycler (Bio-Rad, Hercules,
CA, USA) using 2 ml cDNA template and reagents from
the SuperTaq Plus Kit (Ambion, Austin, TX, USA). Each
sample was analyzed in duplicate. Ampliﬁed PCR products
were visualized under UV illumination on a 1.5% agarose
gel containing ethidium bromide (5 mg/ml, Sigma-Aldrich).
The band intensity of the PCR products was quantiﬁed us-
ing Adobe Photoshop C2 software and normalized to the
GAPDH housekeeping gene. Three independent experi-
ments (n ¼ 3) were performed and the mean  1 SD are
shown in the ﬁgures.
QUANTITATIVE REAL-TIME PCR
Real-time PCR was performed using the same primer se-
quences as stated above. Brieﬂy, 2 ml cDNA template was
combined with reagents from the iQ SYBR Green Super-
mix Kit (Bio-Rad, Hercules, CA) in a total reaction volume of
25 ml. Thermal cycling was performed on the iQ5 Multicolor
Real-Time PCR Detection System (Bio-Rad).NITRITE DETERMINATION ASSAY
Production of NO was assayed by measuring the levels
of the stable NO metabolite, nitrite, using sodium nitrite
resuspended in distilled H2O as the standard. The culture
supernatant (100 ml) was allowed to react with an equal
volume of Griess reagent (one part 0.1% naphthylethyle-
nediamine and one part 1% sulfanilamide in 5% H3PO4)
in a ﬂat bottom 96-well microplate for 10 min at room
temperature in the dark. Nitrite levels were determined
by measuring absorbance at 540 nm using a spectropho-
tometer (SpectraMAX 340; Molecular Devices; Sunnyvale,
CA, USA). Levels of nitrite were normalized to standard
values.
PGE2 HIGH SENSITIVITY IMMUNOASSAY
A commercial PGE2 immunoassay (R&D Systems,
Minneapolis, MN, USA) was used to quantify secreted
PGE2 levels in the cellular supernatant, according to the
manufacturer’s instructions. A PGE2 standard was run in
parallel to the supernatant samples. Brieﬂy, 100 ml of
each supernatant sample was assayed in triplicates on a
96-well microplate coated with a goat anti-mouse polyclonal
antibody. Fifty microliters of PGE2 high sensitivity conjugate
was added to each sample well. Next, 50 ml of PGE2 anti-
body solution was added to each sample well. The micro-
plate was incubated for 18e24 h at 2e8C. After the
incubation period, the microplate wells were aspirated
and washed with PGE2 wash buffer for a total of three
washes. After the last wash, 200 ml of pNPP substrate
was added to the microplate wells. After incubation for 1
h at 37C, 50 ml of Stop Solution was added to the sample
wells. Optical density was measured immediately using the
SpectraMAX 340 microplate reader (Molecular Devices) at
405 nm with wavelength correction set between 570 nm
and 590 nm.
STATISTICAL ANALYSIS
Data are presented as the mean  1 SD of percent of ac-
tivated control samples. Multiple comparisons by one-way
analysis of variance using the StudenteNewmaneKeuls
test were analyzed using SigmaStat statistical software
(Windows Version 3.11, Systat Software Inc., Point Rich-
mond, CA, USA). Differences with P < 0.05 were consid-
ered statistically signiﬁcant. The null hypothesis states
that proinﬂammatory gene expression or production will
be different between control and ASU-treated samples.
Results
THE EFFECT OF ASU ON CYTOKINE GENE EXPRESSION
IN BOVINE CHONDROCYTES
Bovine chondrocytes cultured for 72 h with control media
alone and ASU alone expressed low levels of TNF-a and
IL-1b relative to LPS-activated chondrocytes (Table I and
Fig. 1). Chondrocytes activated for 1 h with 20 ng/ml LPS
expressed increased levels of TNF-a and IL-1b. ASU sup-
pressed TNF-a expression by approximately 50% in acti-
vated chondrocytes when compared to the activated
control. IL-1b expression was reduced by approximately
40% when compared to activated control. ASU profoundly
suppressed TNF-a expression in activated chondrocytes
to levels similar to baseline nonactivated levels (Table I
and Fig. 1).
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PRODUCTION IN BOVINE CHONDROCYTES
Bovine chondrocytes incubated with control media alone
and ASU alone expressed low levels of COX-2 relative to
activated chondrocytes (Table I and Fig. 1). Chondrocytes
also secreted low levels of PGE2 in the cellular supernatant
(Fig. 2). Chondrocytes activated with 20 ng/ml LPS
expressed high levels of COX-2 and secreted a signiﬁcant
increase in PGE2 in the cellular supernatant. ASU downregu-
lated COX-2 expression by greater than 50% when com-
pared to activated control levels (Table I and Fig. 1).
Pretreatment with ASU in activated chondrocytes reduced
PGE2 levels by 40% when compared to activated control
(Fig. 2). COX-2 expression and PGE2 production in ASU-
treated activated chondrocytes was reduced to levels similar
to nonactivated control levels (Table I and Fig. 1).
THE EFFECT OF ASU ON INOS GENE EXPRESSION AND
NITRITE PRODUCTION IN BOVINE CHONDROCYTES
Bovine chondrocytes incubated with control media alone
and ASU alone displayed low levels of iNOS expression
(Table I and Fig. 1) and nitrite production (Fig. 3) compared
to activated chondrocytes. Activated chondrocytes ex-
pressed high levels of iNOS expression. Nitrite levels in-
creased three-fold in activated chondrocytes compared to
nonactivated cells. Activated chondrocytes pretreated with
Fig. 1. The effect of ASU on proinﬂammatory gene expression in
bovine chondrocytes using real-time PCR. Bovine chondrocytes
were incubated with ASU for 72 h and activated with LPS for
24 h. Quantiﬁcation of normalized TNF-a, IL-1b, COX-2 and iNOS
expression are shown. Statistical signiﬁcances between activated
control and other groups were analyzed using the Studente
NewmaneKeuls test (mean  1 SD, n ¼ 3).
Table I
The effect of ASU on proinflammatory gene expression in chon-
drocytes using semiquantitative RT-PCR analysis
Gene C ASU C þ LPS ASU þ LPS
TNF-a 55.4  11.4** 52.3  13.1* 100 53.3  8.7**
IL-1b 55.1  10.7** 55.4  5.4** 100 63.4  9.0**
COX-2 52.1  13.8* 56.2  13.1** 100 44.9  8.9**
iNOS 43.5  20.2** 21.2  3.1** 100 29.1  8.6**
Bovine chondrocytes were incubated with ASU for 72 h and
activated with LPS for 1 h. Normalized gene expression is shown
as percent of activated control (C þ LPS). *P < 0.05; **P < 0.001.ASU showed signiﬁcant downregulation of iNOS expres-
sion by greater than 50% (Table I and Fig. 1). Pretreatment
with ASU suppressed nitrite secretion by 30% in activated
chondrocytes relative to activated control levels (Fig. 3).
THE EFFECT OF ASU ON CYTOKINE GENE EXPRESSION IN
HUMAN THP-1 CELLS
Human THP-1 cells incubated for 72 h with control media
alone and ASU alone expressed low levels of TNF-a and
IL-1b relative to LPS-activated cells (Table II and Fig. 4).
Cells activated with 20 ng/ml LPS showed a signiﬁcant upre-
gulation of TNF-a and IL-1b expression. In activated THP-1
cells pretreated with ASU, TNF-awas reduced by 40%when
compared to activated control cells. Pretreatment with ASU
suppressed IL-1b expression by approximately 50%. ASU
suppressed TNF-a and IL-1b expression to levels similar
to nonactivated control levels (Table II and Fig. 4).
Fig. 2. The effect of ASU on PGE2 levels in chondrocytes. Bovine
chondrocytes were incubated with ASU for 72 h and activated
with LPS for 24 h. Mean PGE2 levels released into the cellular
supernatant are shown as percent of activated control. Statistical
signiﬁcances between activated control and other groups were ana-
lyzed using the StudenteNewmaneKeuls test (mean  1 SD, n ¼ 3).
Fig. 3. The effect of ASU on nitrite levels in chondrocytes. Bovine
chondrocytes were incubated with ASU for 72 h and activated
with LPS for 24 h. Mean nitrite levels released into the cellular su-
pernatant are shown as percent of activated control. Statistical sig-
niﬁcances between activated control and other groups were
analyzed using the StudenteNewmaneKeuls test (mean  1 SD,
n ¼ 3).
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In the present study, we show for the ﬁrst time that the
anti-inﬂammatory effects of ASU is not restricted to chon-
drocytes and ﬁbroblasts but extends to monocyte/macro-
phage tissue surrogate cells. We demonstrate that ASU
suppresses the gene expression of potent proinﬂammatory
cytokines, TNF-a and IL-1b, in an LPS-stimulated mono-
cyte/macrophage-like cell model in addition to suppressing
gene expression of TNF-a, IL-1b, COX-2 and iNOS in cul-
tured chondrocytes. Furthermore, we conﬁrm the results
of previous studies that ASU suppresses PGE2 and NO
synthesis in chondrocytes grown in monolayer. This ﬁnding
suggests that ASU acts on multiple cell types involved in in-
ﬂammation and thus is likely to produce beneﬁcial effects at
different sites within joints affected in OA.
The joint degradation associated with OA involves inﬂam-
mation of the surrounding cartilage, synovial membrane, and
bone tissues. Various studies have documented the deleteri-
ous effects of synovial macrophages in inﬂamed joints. In an
experimental murine model of OA, synovial macrophages
were implicated in the development of osteophyte formation
and ﬁbrosis28. Another study identiﬁed a positive relationship
between macrophage density, duration of disease, and se-
verity of disease in dogs afﬂicted with osteoarthritic joints25.
Studies havealso suggested thatmacrophagesareaprimary
source of proinﬂammatory cytokines that are found at ele-
vated levels in the synovial tissue of OA patients26,29e31.
These results collectively suggest thatmacrophages are cru-
cial to the initiation andmaintenance of synovial inﬂammation
seen inmanyOA joints. In this study, we studied the effects of
Table II
The effect of ASU on proinflammatory gene expression in THP-1
cells using semiquantitative RT-PCR analysis
Gene C ASU C þ LPS ASU þ LPS
TNF-a 53.4  9.5** 45.9  15.8** 100 60.3  4.6**
IL-1b 56.1  15* 64.1  14.3* 100 51.1  8.0*
THP-1 cells were incubated with ASU for 72 h and activated with
LPS for 1 h. Normalized gene expression is shown as percent of
activated control (C þ LPS). *P < 0.05; **P < 0.001.
Fig. 4. The effect of ASU on cytokine gene expression in THP-1
cells using real-time PCR. THP-1 cells were incubated with ASU
for 72 h and activated with LPS for 24 h. Quantiﬁcation of normal-
ized TNF-a and IL-1b expression is shown. Statistical signiﬁcances
between activated control and other groups were analyzed using
the StudenteNewmaneKeuls test (mean  1 SD, n ¼ 3).ASU on isolated bovine chondrocytes and humanmonocyte/
macrophage-like THP-1 cells. Human THP-1 cells are well-
documented to serve as a monocyte/macrophage surrogate
model commonly used in studies examining proinﬂammatory
mediators of the immune response32,33. These cells prolifer-
ate quickly, yielding a sufﬁcient number of viable cells for
analysis. Our observation that ASU suppresses proinﬂam-
matory gene expression in a macrophage prototype sug-
gests that ASU may also have an anti-inﬂammatory effect
on synovial macrophages as well. By mediating the proin-
ﬂammatory response in synovial macrophages and other
cell types within the OA joint, ASU can serve as a potential
moderator for the reduction of joint inﬂammation.
As the only cellular component of articular cartilage, chon-
drocytes are capable of mediating proinﬂammatory gene
expression in response to tissue injury34. Bovine chondro-
cytes were utilized in this study due to the abundant supply
of cells obtained from tissue digestion of the cartilage. The
isolated chondrocytes were primary cells that showed no
phenotypic drift through several passages and maintained
the articular cartilage phenotype35. In addition, the critical
role that cytokines, COX-2, and iNOS play in the pathogene-
sis of OA has been studied extensively in bovine chondrocy-
tes36e39. Cytokines have been shown to activate degradative
enzymes in cartilage itself and in synovial tissue. Therefore,
suppression of cytokine gene expression is essential to
reduce the progression of cartilage damage. IL-1b and
TNF-a are the primary cytokinesmediating the pathogenesis
of OA34. Studies have shown that abnormally high levels of
IL-1b and TNF-a are present in the synovial ﬂuid, synovium,
and cartilage tissue of OA patients5. In in vitro studies, both
IL-1bandTNF-a stimulate secretion of prostaglandins and in-
crease the activity of matrix-degrading proteinases such as
collagenase, gelatinase, proteoglycanase, stromelysin, and
plasminogen activator4,40,41. Though IL-1b is physiologically
more potent than TNF-a, animal studies have suggested that
the two cytokines act synergistically to stimulate cartilage
degradation that exceeds the damage observed with either
cytokine alone42. That ASU downregulates gene expression
of both IL-1b and TNF-a in chondrocytes and monocytes
suggest that it may act to slow the degradative process of
cartilage breakdown.
In addition to matrix-degrading enzymes, IL-1b and TNF-a
also induce the synthesis of the COX-2 and iNOS enzymes.
Induction of COX-2 and iNOS results in elevated levels of
PGE2 and NO, which leads to cartilage degradation, inhibi-
tion of matrix synthesis, and chondrocyte apoptosis43e46.
In contrast, suppression of PGE2 and NO production has
been documented to relieve pain and inﬂammation associ-
ated with OA symptoms47,48. Our study conﬁrms that ASU
downregulates COX-2 and iNOS gene expression, resulting
in a reduction of PGE2 and nitrite production in the cellular
supernatant.
For the ﬁrst time, this study demonstrates that ASU acts
as a potent inhibitor of cytokines, COX-2, and iNOS gene
expression while also suppressing the production of PGE2
and nitrite in both chondrocytes and monocyte/macro-
phage-like cells. Previous research has shown that these
mediators are important in the pathogenesis of OA and
that the reduction in these mediators has been associated
with amelioration of cartilage breakdown. Our in vitro study
suggests that ASU helps to decrease the expression and
production of such inﬂammatory mediators in multiple cell
types. As immune cells localized in the synovial tissue,
monocyte/macrophages are known to play a principal role
in the pathogenesis of arthritic conditions. Chondrocytes
are the only cellular component of articular cartilage and
1254 R. Y. Au et al.: ASU effect on chondrocytes and monocytesare capable of phenotype modulation, making these cells
pivotal in the progression of joint diseases. By evaluating
the effects of ASU on both cell types, we have shown that
the anti-inﬂammatory effects of ASU are not restricted to
chondrocytes, but also affect monocyte/macrophage-like
cells that are associated with the synovial membrane. While
the ability of ASU to reduce proinﬂammatory targets in mul-
tiple tissue cell types suggest its potential role as an alterna-
tive or complement to traditional NSAID use to treat OA,
whether our in vitro data can be extrapolated to explain all
the in vivo effects seen in OA patients remain to be further
examined.
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